Phase II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Teceleukin, and Zoledronic acid in Patients With Stage IV Renal Cell Carcinoma
Not Applicable
- Conditions
- Cytokine refractory Renal cell carcinoma
- Registration Number
- JPRN-UMIN000004482
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1) No current treatment with any anti-cancer drugs 2) No brain metastasis, No hypercalcemia that require medication, No C-reactive protein with an infectious disease that requires medication, No active infection with hepatitis virus or HIV, No current treatment with steroids, No poorly controlled DM or heart failure or arrhythmia, No autoimmune disease and interstitial pneumonia, No other malignancy, No bone of organ transplant recipient, Not pregnant nor nursing, No mental disorder 3) Other patients judged to be ineligible by the attending investigators were also excluded from the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease control rate: The best overall responses is defined by the RECIST criteria. The target lesions were scanned using helical CT at lease 6 weeks interval during the clinical trial. The disease control rate was determined the proportion of CR+PR+SD.
- Secondary Outcome Measures
Name Time Method